Technical Analysis for INBX - Inhibrx, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.35% | |
| Pocket Pivot | Bullish Swing Setup | 0.35% | |
| Volume Surge | Other | 0.35% | |
| Bollinger Band Squeeze | Range Contraction | 0.35% | |
| Inside Day | Range Contraction | 0.35% | |
| 20 DMA Resistance | Bearish | 1.03% | |
| Bollinger Band Squeeze | Range Contraction | 1.03% | |
| Inside Day | Range Contraction | 1.03% | |
| 20 DMA Resistance | Bearish | 1.29% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 9 hours ago |
| Rose Above Upper Bollinger Band | about 10 hours ago |
| Upper Bollinger Band Resistance | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Possible NR7 | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/24/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.79 |
| 52 Week Low | 14.305 |
| Average Volume | 473,076 |
| 200-Day Moving Average | 27.80 |
| 50-Day Moving Average | 34.69 |
| 20-Day Moving Average | 34.25 |
| 10-Day Moving Average | 34.33 |
| Average True Range | 0.44 |
| RSI (14) | 50.74 |
| ADX | 19.36 |
| +DI | 15.75 |
| -DI | 15.41 |
| Chandelier Exit (Long, 3 ATRs) | 33.51 |
| Chandelier Exit (Short, 3 ATRs) | 35.06 |
| Upper Bollinger Bands | 34.60 |
| Lower Bollinger Band | 33.89 |
| Percent B (%b) | 0.85 |
| BandWidth | 2.06 |
| MACD Line | -0.12 |
| MACD Signal Line | -0.18 |
| MACD Histogram | 0.0609 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 34.96 | ||||
| Resistance 3 (R3) | 34.98 | 34.83 | 34.88 | ||
| Resistance 2 (R2) | 34.83 | 34.71 | 34.82 | 34.86 | |
| Resistance 1 (R1) | 34.66 | 34.64 | 34.75 | 34.65 | 34.83 |
| Pivot Point | 34.52 | 34.52 | 34.56 | 34.51 | 34.52 |
| Support 1 (S1) | 34.35 | 34.39 | 34.43 | 34.33 | 34.15 |
| Support 2 (S2) | 34.20 | 34.32 | 34.19 | 34.12 | |
| Support 3 (S3) | 34.03 | 34.20 | 34.10 | ||
| Support 4 (S4) | 34.02 |
